0001011060 2025-04-01 2026-03-31 0001011060 2025-09-30 0001011060 2026-07-14 0001011060 2026-03-31 0001011060 2025-03-31 0001011060 NORD:SeriesAJuniorMember 2026-03-31 0001011060 NORD:SeriesAJuniorMember 2025-03-31 0001011060 NORD:PreferredStockUndesignatedMember 2026-03-31 0001011060 NORD:PreferredStockUndesignatedMember 2025-03-31 0001011060 2024-04-01 2025-03-31 0001011060 us-gaap:CommonStockMember 2024-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001011060 us-gaap:RetainedEarningsMember 2024-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2024-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001011060 us-gaap:ParentMember 2024-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2024-03-31 0001011060 2024-03-31 0001011060 us-gaap:CommonStockMember 2025-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2025-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2025-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001011060 us-gaap:RetainedEarningsMember 2025-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2025-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001011060 us-gaap:ParentMember 2025-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2025-03-31 0001011060 us-gaap:CommonStockMember 2024-04-01 2025-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-04-01 2025-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-04-01 2025-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-31 0001011060 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2024-04-01 2025-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2025-03-31 0001011060 us-gaap:ParentMember 2024-04-01 2025-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2024-04-01 2025-03-31 0001011060 us-gaap:CommonStockMember 2025-04-01 2026-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2025-04-01 2026-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2025-04-01 2026-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2026-03-31 0001011060 us-gaap:RetainedEarningsMember 2025-04-01 2026-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2025-04-01 2026-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2026-03-31 0001011060 us-gaap:ParentMember 2025-04-01 2026-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2025-04-01 2026-03-31 0001011060 us-gaap:CommonStockMember 2026-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2026-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2026-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001011060 us-gaap:RetainedEarningsMember 2026-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2026-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001011060 us-gaap:ParentMember 2026-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2026-03-31 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2021-10-12 2021-10-12 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-11 2022-03-11 0001011060 NORD:FirstClosingMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-11 2022-03-11 0001011060 NORD:SecondClosingMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 2022-03-15 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 2022-03-15 0001011060 NORD:ContributionAgreementMember 2023-02-23 2023-02-23 0001011060 NORD:MagMileCapitalIncMember 2023-06-01 0001011060 NORD:OrocidinASMember 2024-05-13 0001011060 NORD:OrocidinASMember 2024-05-13 2024-05-13 0001011060 NORD:StockPurchaseAgreementMember 2024-11-08 2024-11-08 0001011060 2024-11-08 0001011060 NORD:BioConvertASMember 2024-11-11 0001011060 NORD:BioConvertASMember 2024-11-11 2024-11-11 0001011060 us-gaap:CommonStockMember NORD:OrocidinASMember 2024-11-12 2024-11-12 0001011060 us-gaap:RestrictedStockMember NORD:OrocidinASMember 2024-11-12 2024-11-12 0001011060 NORD:MrRitterMember NORD:DirectorsAgreementMember 2025-08-07 0001011060 NORD:MessrsJensenMember NORD:DirectorsAgreementMember 2025-08-07 2025-08-07 0001011060 NORD:MessrsJensenMember NORD:DirectorsAgreementMember 2025-08-07 0001011060 NORD:MrRitterMember NORD:DirectorsAgreementMember 2025-08-07 2025-08-07 0001011060 NORD:AlteralTherapeuticsMember 2025-10-31 0001011060 NORD:NoviTheraMember 2025-10-31 0001011060 NORD:OrocidinASMember 2024-12-31 0001011060 NORD:BioConvertASMember 2024-12-31 0001011060 2024-11-08 2024-11-08 0001011060 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001011060 us-gaap:EmployeeStockOptionMember 2025-04-01 2026-03-31 0001011060 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001011060 NORD:BioConvertMember 2024-04-01 2025-03-31 0001011060 NORD:BioConvertMember 2025-03-31 0001011060 NORD:OrocidinASMember 2024-04-01 2025-03-31 0001011060 srt:SubsidiaryIssuerMember NORD:OrocidinASMember 2024-04-01 2024-06-30 0001011060 NORD:BioConvertASMember 2024-04-01 2025-03-31 0001011060 srt:SubsidiaryIssuerMember NORD:BioConvertAPSMember 2024-10-01 2024-12-31 0001011060 NORD:OrocidinASMember 2024-05-13 0001011060 NORD:OrocidinASMember 2024-11-12 0001011060 NORD:NoviTheraMember 2026-03-31 0001011060 NORD:OrocidinASMember 2025-03-31 0001011060 NORD:BioConvertASMember 2025-03-31 0001011060 NORD:OrocidinASMember 2025-04-01 2026-03-31 0001011060 NORD:BioConvertASMember 2025-04-01 2026-03-31 0001011060 NORD:OrocidinASMember 2026-03-31 0001011060 NORD:BioConvertASMember 2026-03-31 0001011060 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0001011060 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2026-04-30 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2023-06-19 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember 2023-06-19 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember 2023-06-20 0001011060 NORD:GKPartnersMember 2022-04-01 0001011060 NORD:GKPartnersMember 2023-12-22 0001011060 NORD:GKPartnersMember 2024-04-01 2025-03-31 0001011060 NORD:GKPartnersMember 2025-03-31 0001011060 NORD:GKPartnersMember 2024-12-30 0001011060 srt:MinimumMember NORD:GKPartnersMember 2025-03-31 0001011060 srt:MaximumMember NORD:GKPartnersMember 2025-03-31 0001011060 NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2025-04-01 2026-03-31 0001011060 NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2026-03-31 0001011060 NORD:GKPartnersApsMember NORD:ShortTermLeaseAgreementMember 2025-07-01 2025-07-31 0001011060 NORD:GKPartnersApsMember 2025-04-01 2026-03-31 0001011060 NORD:MrBennettYankowitzMember 2025-04-01 2026-03-31 0001011060 NORD:MrBennettYankowitzMember 2024-04-01 2025-03-31 0001011060 NORD:MrBennettYankowitzMember 2026-03-31 0001011060 NORD:MrBennettYankowitzMember 2025-03-31 0001011060 NORD:HenrikRoufMember 2023-04-01 2023-04-01 0001011060 NORD:HenrikRoufMember 2024-04-08 2024-04-08 0001011060 NORD:HenrikRoufMember 2025-07-01 2025-07-01 0001011060 NORD:MrBennettYankowitzMember 2023-04-01 2023-04-01 0001011060 NORD:MrBennettYankowitzMember 2024-04-08 2024-04-08 0001011060 NORD:MrBennettYankowitzMember 2025-07-01 2025-07-01 0001011060 NORD:NpBioinnovationASMember 2023-02-23 0001011060 srt:BoardOfDirectorsChairmanMember 2024-06-03 2024-06-03 0001011060 srt:DirectorMember 2024-06-03 2024-06-03 0001011060 NORD:DarlingtonGroupLLCMember 2025-10-01 0001011060 2025-10-01 2025-10-31 0001011060 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001011060 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001011060 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001011060 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001011060 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001011060 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001011060 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001011060 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001011060 us-gaap:PreferredStockMember 2026-03-31 0001011060 us-gaap:PreferredStockMember 2025-04-01 2026-03-31 0001011060 NORD:SeriesAJuniorMember 2025-04-01 2026-03-31 0001011060 NORD:PreferredStockUndesignatedMember 2026-03-31 0001011060 NORD:PreferredStockUndesignatedMember 2025-03-31 0001011060 NORD:PrivateInvestorsMember 2025-04-01 2026-03-31 0001011060 srt:MinimumMember NORD:PrivateInvestorsMember 2026-03-31 0001011060 srt:MaximumMember NORD:PrivateInvestorsMember 2026-03-31 0001011060 NORD:BoardOfDirectorsMember 2025-08-31 0001011060 2025-08-01 2025-08-31 0001011060 us-gaap:CommonStockMember 2025-10-01 2025-10-01 0001011060 us-gaap:CommonStockMember 2025-10-01 0001011060 2024-06-07 0001011060 NORD:IncentiveStockOptionsMember 2024-06-07 0001011060 us-gaap:PerformanceSharesMember 2024-06-07 0001011060 us-gaap:EmployeeStockOptionMember 2026-03-31 0001011060 us-gaap:PerformanceSharesMember 2026-03-31 0001011060 NORD:ServiceSharesMember 2026-03-31 0001011060 us-gaap:EmployeeStockOptionMember 2025-04-01 2026-03-31 0001011060 us-gaap:PerformanceSharesMember 2025-04-01 2026-03-31 0001011060 us-gaap:PerformanceSharesMember 2024-11-01 2024-11-30 0001011060 NORD:MonteCarloMember 2025-04-01 2026-03-31 0001011060 NORD:ThirdPartyMember 2025-04-01 2026-03-31 0001011060 NORD:ThirdPartyMember 2024-04-01 2025-03-31 0001011060 NORD:OrocidinASMember 2024-11-11 2024-11-11 0001011060 NORD:OrocidinASMember 2024-11-11 0001011060 NORD:OrocidinASMember 2025-03-31 0001011060 NORD:BioConvertASMember 2025-03-31 0001011060 NORD:OrocidinASMember 2025-04-01 2026-03-31 0001011060 NORD:BioConvertASMember 2025-04-01 2026-03-31 0001011060 NORD:OrocidinASMember 2026-03-31 0001011060 NORD:BioConvertASMember 2026-03-31 0001011060 us-gaap:WarrantMember 2025-03-31 0001011060 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001011060 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001011060 us-gaap:WarrantMember 2026-03-31 0001011060 us-gaap:DomesticCountryMember 2025-04-01 2026-03-31 0001011060 us-gaap:ForeignCountryMember 2025-04-01 2026-03-31 0001011060 NORD:TwoDemandPromissoryNotesMember NORD:ReddingtonMember 2026-02-18 0001011060 NORD:AdditionalDemandPromissoryNoteMember NORD:ReddingtonMember 2026-03-06 0001011060 NORD:TwoDemandPromissoryNotesMember NORD:ReddingtonMember 2025-04-01 2026-03-31 0001011060 NORD:TwoDemandPromissoryNotesMember NORD:ReddingtonMember 2024-04-01 2025-03-31 0001011060 us-gaap:RestrictedStockMember NORD:FivePrivateInvestorsMember 2026-03-01 2026-03-31 0001011060 us-gaap:RestrictedStockMember NORD:FivePrivateInvestorsMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0001011060 us-gaap:RestrictedStockMember NORD:FivePrivateInvestorsMember 2026-03-31 0001011060 us-gaap:RestrictedStockMember NORD:FivePrivateInvestorsMember us-gaap:SubsequentEventMember 2026-04-30 0001011060 NORD:HenrikRoufMember us-gaap:SubsequentEventMember 2026-06-30 0001011060 NORD:HenrikRoufMember us-gaap:SubsequentEventMember 2026-03-01 2026-06-30 iso4217:USD shares iso4217:USD shares pure false FY 0001011060

http://fasb.org/us-gaap/2026#IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

10-K true 2026-03-31 --03-31 2026 false 001-11737 NORDICUS PARTNERS CORPORATION DE 04-3186647 280 South Beverly Dr. Suite 505 Beverly Hills CA 90212 (310) 666-0750 Common Stock, $0.001 par value per share No No Yes Yes Non-accelerated Filer true false false true false false 21126694 19173896 We use, store and process data for and about our employees, partners and suppliers. We have implemented a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats to this data, our systems and business operations. Cyber Risk Management and Strategy <div><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250401__20260331_z2WxtOv5TYvi">Under the oversight of the Audit Committee (and before its creation in November 2025, the full Board of Directors), we have implemented and maintain a risk management program that includes processes for the systematic identification, assessment, management, and treatment of cybersecurity risks. We utilize <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250401__20260331_zsBiGkWfFTH3">third parties and consultants to assist in the identification and assessment of risks, including to support tabletop exercises and to conduct security testing, if deemed necessary. We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google Enterprise to provide protection against cybersecurity threats. We continue to evaluate and enhance our systems, controls, and processes where possible, including in response to actual or perceived threats specific to us or experienced by other companies. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250401__20260331_zoOw1j1P2u74">Risks from cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition. </div> Under the oversight of the Audit Committee (and before its creation in November 2025, the full Board of Directors), we have implemented and maintain a risk management program that includes processes for the systematic identification, assessment, management, and treatment of cybersecurity risks. true Risks from cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition. 5525 We have audited the accompanying consolidated balance sheets of Nordicus Partners Corporation and Subsidiaries (“the Company”) as of March 31, 2026 and 2025, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended March 31, 2026, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and 2025, and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2026, in conformity with accounting principles generally accepted in the United States of America. Fruci & Associates II, PLLC Spokane, Washington

20878

19914

512006

37656

532884

57570

45506471 42708079

8207

27161000

25490751

2250000

1925000

4784

64929

75463346

70246329

1111096

1062661

60000

1171096

1062661

10054367

9318414

11225463

10381075

0.001

500000

0.001

4500000

0.001

50000000

19128896

17252502

19187

17253

57796

154

108722

30328

110842830

106047792

4314899

615385

-50786534

-46784848

64281660

59865254

-43777

64237883

59865254

75463346

70246329

5000

615284

662554

940727

351773

317960 248878

890055

331724

1606972

1329436

4370998

2924365

-4370998

-2919365

642

200

172715

325000

175000

164

324194

2085

-4046804

-2917280

-4046804

-2917280

-45118

-15959

-4001686

-2901321

3700073

618233

-301613

-2283088

559

-302172

-2283088

-0.22

-0.32

18121508

9205061

1110226

1110

45696761

-43883527

-30328

-2848

1781168

3800000

3800

18996200

19000000

92776

895100

895193

167000

30000

138949

138979

13886 13886 13886

19500

-20

450000

183663

9667

193330

527625

12000000

12000

38985120

38997120

200000 200 443508 443708 -443708

-2901321

-15959

-2917280

618233

17252502

17253

106047792

-46784848

-30328

615385

59865254

17252502

17253

106047792

-46784848

-30328

615385

59865254

137544

1850036

1850

4351992

4353842

84000

304716

304800

786

782

1568

57642

78394

3699514

559

3700073

-4001686

-45118

-4046804

19128896

19187

110842830

-50786534

-108722

4314899

64281660

-43777

64237883

19128896

19187

110842830

-50786534

-108722

4314899

64281660

-43777

64237883

-4046804

-2917280

304800 138979

137544

527625

172715

-163

325000

175000

1559

5198

5174

403553

8784

1160

60089

-81637

1032045

-84115

-4324775

-1284615

7597

17755

2374

150186

-10158

147812

2880

78394

4353842

60000

193330

889477

4335448

1079927

515

-56876

449

26857

19914

49933

20878

19914

1568 39000000

19000000

167000 13886

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS We were founded in 1993, reincorporated in Delaware in 2007, changed our name to AdvanSource Biomaterials Corporation in 2008 and changed our name to EKIMAS Corporation in 2020. On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”), providing for Reddington’s purchase of a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211012__20211012__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z3yG7vSSB7c8" title="Number of shares issued">511,448 shares of our common stock, on a post-split basis, or approximately <span id="xdx_907_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20211012__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zRS14RZQBiif" title="Percentage of outstanding common stock">90% of our total outstanding common stock, for total cash consideration of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211012__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z5SmBSUGz1Ma" title="Cash consideration for shares">400,000. Reddington purchased the common stock in two tranches, which closed on October 12, 2021 (the “First Closing”) and March 15, 2022. Pursuant to the SPA, the Company effected a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20220311__20220311__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zc2L4GsGKTt" title="Reverse stock split">1-for-50 reverse stock split on March 11, 2022 (the “Reverse Split”). On a post-split basis, Reddington acquired <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220311__20220311__srt--StatementScenarioAxis__custom--FirstClosingMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zksFzOPWBH7l" title="Stock issued during period, shares, new issues">42,273 at the First Closing and an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220315__20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__srt--StatementScenarioAxis__custom--SecondClosingMember_zs8qIcKPcW1f" title="Stock issued during period, shares, new issues">469,175 shares at the March 15, 2022 second closing, after which Reddington owned <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zHoIPZTw516k" title="Common stock owned">511,448 shares of our common stock, or approximately <span id="xdx_90F_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20220315__20220315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zYqLsJ3FwCyb" title="Percentage of outstanding common stock">90% of our total outstanding common stock. On February 23, 2023, the Company acquired NP Bioinnovation A/S (formerly Nordicus Partners A/S and Managementselskabet af 12.08.2020 A/S), a Danish stock corporation, pursuant to a contribution agreement with NP Bioinnovation A/S, GK Partners ApS, Henrik Rouf and Life Science Power House ApS. The sellers contributed <span id="xdx_905_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20230223__20230223__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_z7qILAi9QJzb" title="Percentage of outstanding common stock">100% of the issued and outstanding capital stock of NP Bioinnovation A/S to the Company in exchange for an aggregate of 250,000 shares of the Company’s common stock, and NP Bioinnovation A/S became a wholly owned subsidiary of the Company. On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company. On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On June 1, 2023, the Company acquired a <span id="xdx_90D_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230601__us-gaap--BusinessAcquisitionAxis__custom--MagMileCapitalIncMember_zjZu3xt64bY4" title="Equity interest acquired, percentage">4.99% interest in Mag Mile Capital, Inc., a commercial real estate mortgage banking firm headquartered in Chicago. On June 9, 2023, Mr. Tom Glaesner Larsen resigned as a director of the Company and Henrik Keller was appointed as his replacement. On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. Subsequently on March 10, 2025, Managementselskabet af 12.08.2020 A/S changed its name to NP Bioinnovation A/S. On May 13, 2024, the Company acquired a <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zqdTmWG001s6" title="Ownership percentage acquired">95% interest in Orocidin A/S (“Orocidin”), a Danish preclinical-stage biotechnology company advancing next-generation periodontitis therapies, in exchange for <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240513__20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_za6uXFcGq5mb" title="Number of shares issued for acquisition">3,800,000 restricted shares of the Company’s common stock. On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement. On November 8, 2024, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock, rounding up for fractional shares. The reverse stock split had no effect on the Company’s authorized shares of common stock or preferred stock, and the par value of each class remained $0.001. All common stock share, option, warrant and per-share amounts, except authorized but unissued shares, have been retroactively adjusted in these consolidated financial statements and related disclosures. On November 11, 2024, the Company announced that it had entered into an agreement to acquire <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20241111__us-gaap--BusinessAcquisitionAxis__custom--BioConvertASMember_zjNVgBUPgV46" title="Ownership percentage acquired">100% of the outstanding shares of Bio-Convert A/S (“Bio-Convert”), a Denmark-based preclinical-stage biotechnology company developing treatments for oral leukoplakia, in exchange for <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20241111__20241111__us-gaap--BusinessAcquisitionAxis__custom--BioConvertASMember_z90bSsSpj8Gg" title="Number of shares issued for acquisition">12,000,000 restricted shares of the Company’s common stock. On November 12, 2024, the Company acquired the remaining <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241112__20241112__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zElqsM3ntJc7" title="Restricted Shares issued">29,663 outstanding shares, or approximately <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20241112__20241112__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOsNo510voPe" title="Outstanding shares percentage">5%, of Orocidin A/S in exchange for <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241112__20241112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIdrtbGeC5C4" title="Number of shares issued">200,000 restricted shares of the Company’s common stock, after which Orocidin A/S became a wholly owned subsidiary of the Company. On August 7, 2025, (1) Henrik Keller resigned from the Board of Directors of the Company, (2) the Board increased its size from three to five members and (3) Torben S. Jensen, Kim T. Mücke and Andrew J. Ritter were appointed to fill the resulting vacancies. The Company executed a director agreement with each of Messrs. Jensen, Mücke and Ritter, under which each will receive an annual cash retainer of $<span id="xdx_902_ecustom--AnnualCashRetainerAmount_iI_c20250807__us-gaap--TypeOfArrangementAxis__custom--DirectorsAgreementMember__srt--TitleOfIndividualAxis__custom--MrRitterMember_zlzBhElrvWq9" title="Annual cash retainer amount">10,000, payable in two installments per calendar year in accordance with the Company’s standard compensation plan for Board members. Messrs. Jensen and Mücke also each received options to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250807__20250807__us-gaap--TypeOfArrangementAxis__custom--DirectorsAgreementMember__srt--TitleOfIndividualAxis__custom--MessrsJensenMember_zmSFvsjWv29" title="Share based compensation arrangement by share based payment award options grants in period gross, shares">25,000 shares of the Company’s common stock at $1.90 per share, and Mr. Ritter received options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250807__20250807__us-gaap--TypeOfArrangementAxis__custom--DirectorsAgreementMember__srt--TitleOfIndividualAxis__custom--MrRitterMember_zhqk4hRJph6b" title="Share based compensation arrangement by share based payment award options grants in period gross, shares">50,000 shares of the Company’s common stock at $1.90 per share. All such options were fully vested on the date of grant and issued as incentive stock options under, and subject to the terms and conditions of, the Company’s 2024 Stock Incentive Plan. In October 2025, the Company formed NoviThera ApS (“NoviThera”) to research and develop a monoclonal antibody (MaB) therapy for the treatment of psoriasis. The invention and initial development were made and performed by Alteral Therapeutics (“Alteral”), a Denmark-domiciled related party of the Company. Mr. Allan Wehnert, who controls Alteral, was appointed Chief Executive Officer of NoviThera. In exchange for contributing intellectual property to NoviThera, Alteral received a <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251031__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlteralTherapeuticsMember_zxy3vw9SCFn9" title="Equity method investment ownership percentage">49.9% ownership interest in NoviThera, and the Company retained a 50.1% ownership interest. On November 10, 2025, the Board created (1) a Nominating and Corporate Governance Committee, consisting of Peter Severin (Chairman), Kim T. Mücke and Andrew J. Ritter; (2) an Audit Committee, consisting of Kim T. Mücke (Chairman), Peter Severin and Andrew J. Ritter; and (3) a Compensation Committee, consisting of Andrew J. Ritter (Chairman), Peter Severin and Kim T. Mücke. The Board also adopted a Code of Conduct and Ethics, an Insider Trading Policy, a Whistleblower Policy and a Compensation Recovery Policy. Description of Business Nordicus Partners Corporation (“Nordicus” or the “Company”) is a U.S. publicly listed biotech company specializing in developing breakthrough therapeutics in diseases with unmet medical needs. Nordicus focuses on acquiring and developing drugs from innovative biotech companies in the Nordics, a region known for its brilliant scientists, exceptional life science ecosystem and drug discoveries and developments. Nordicus is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs – starting with oral disorders. Its scientific foundation targets inflammation and immune modulation. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. Nordicus’ portfolio diversification strategy positions it as a stable and resilient company, mitigating risk with significant upside potential. Our Approach and Value Creation Process Nordicus employs a 4-step value creation process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Scout and Accelerate: Nordicus targets high-impact potential companies, providing capital, resources and expertise to drive critical milestones such as patent filings and clinical trials.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Acquire and Exit: Nordicus acquires controlling stakes to maximize value creation and exit at premium multiples.</td></tr></table> We scout the Nordic region looking for early-stage life sciences companies developing drugs or treatments for diseases in high growth markets with significant unmet medical needs, all in potential multibillion USD markets. After a vigorous due diligence process, the chosen companies will be offered to join Nordicus’ accelerator program. Once the chosen companies have become accelerator clients, Nordicus takes an active role in advising the management team, assisting with strengthening the companies’ Board of Directors and establishing Advisory Boards including making introductions to strategic partners and talent. Once the milestones – set by Nordicus – are met, Nordicus will typically offer to acquire the companies outright. The first three acquisitions will be all-stock transactions, with the first two acquisitions (Orocidin A/S and Bio-Convert A/S) having already been completed, fitting Nordicus’ criteria of inclusion. Nordicus aims to take all portfolio companies’ drug developments through Phase I. Upon completion of Phase I, the following options will be considered: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sale or merger of the portfolio company.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Further development through the next clinical phases.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Strategic partnership with a large pharmaceutical company that will invest in Nordicus for further drug development.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stand-alone Initial Public Offering (IPO).</td></tr></table> Nordicus’ current life sciences portfolio consists of two promising preclinical biotechnology companies in Orocidin A/S and Bio-Convert A/S led by the accomplished pharmacologist, Allan Wehnert, who serves as CEO of both companies. In October 2025 formed a third subsidiary, NoviThera, also to be led by Alan Wehnert. Orocidin A/S is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis, with Bio-Convert A/S focused on a treatment against oral leukoplakia (OLK) – an oral potentially malignant disorder – by developing a novel proprietary mucoadhesive oral topical formulation designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia. The companies’ innovative breakthroughs are further strengthened by their oral formulations ensuring prolonged adhesion for 12-24 hours and controlled release of the active ingredient, enhancing drug efficacy and patients’ outcomes – a major advancement over normal gels and creams. NoviThera is developing a drug for the treatment of psoriasis, an Immune-medicated inflammatory disease that causes keratinocyte hyperproliferation and inflammation. Orocidin A/S Orocidin A/S has successfully completed a 14-day toxicology study in hamsters and two tests of effectiveness in a Beagle Dog Study and a Wistar Rat Study. In the 14-days toxicology study, all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues. The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study. The Beagle Dog Study is the first study that shows Orocidin A/S drug, QR-01, having a direct effect on periodontitis diagnosed beagle dogs. The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis. The dogs demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal disease. Moreover, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period. This represents a significant milestone for Orocidin’s lead product, QR-01, and strengthens Nordicus’ and Orocidin’s confidence as Orocidin prepare for the upcoming human pilot efficacy study. In the second efficacy study, rats with induced periodontitis treated with QR-01 demonstrated improvements in Probing Depth (PD-mm), Gingival Index (GI), Bleeding on Probing (BOP) and Plaque Levels (PL). More importantly, lower bone loss was demonstrated in treated rats compared to non-treated rats measured by micro-CT scanning. Until now, this has not been demonstrated. In summary, Orocidin has now demonstrated efficacy in treating periodontitis in two different animals using 2 methods. The first Phase IIa clinical trials study in patients is now anticipated to start in the first half of 2027 at the University of Copenhagen in Denmark. Bio-Convert Bio-Convert’s QR-02 compound targets Oral Leukoplakia (OLK), which are potentially pre-cancerous lesions in the mouth, with up to a 30% conversion rate to oral cancer. No approved medical treatment exists for OLK, with surgery the only true alternative. The company’s proprietary oral gel QR-02 has several unique advantages, including antitumor & antiviral effects, reducing the risk of dysplasia and enabling more precise and efficient treatment, compared to any methods used today. Bio-Convert obtained a toxicity waiver from the Danish Medicine Agency’s (DKMA) for QR-02 and is currently finalizing its GMP (Good Manufacturing Practice) product to be completed by December 2026 in Germany. Bio-Convert anticipates moving into Phase IIa clinical trials in Europe beginning the first half of 2027. NoviThera NoviThera’s QR-04 compound has the goal to develop a novel anti-monoclonal antibody treatment designed to cure psoriasis or prevent its occurrence. Currently, no permanent cure for psoriasis exists, leading to a significant unmet medical need for patients and huge market potential. NoviThera recently completed a study in mice, and with such study demonstrated biological proof of concept.

511448

0.90

400000

1-for-50 reverse stock split

42273

469175

511448

0.90 1

250000

0.0499

0.95

3800000

1-for-10 reverse stock split

0.001

12000000

29663

0.05

200000

10000

25000

1.90

50000

1.90

0.499

0.501

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Reverse Stock Split On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding Common Stock, rounding up to account for any fractional shares. The reverse stock split had no effect on the Company’s authorized shares of Common Stock or Preferred Stock and the par value of both remained unchanged at $0.001. All Common Stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these condensed consolidated financial statements and related disclosures. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill, and the fair value of assets acquired and liabilities assumed in business combinations. Concentration of Credit Risk The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. The Company also maintains cash in foreign bank accounts that are not federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in its accounts. The Company believes it is not exposed to any significant credit risk on cash. Cash and Cash Equivalents Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of March 31, 2026 and March 31, 2025. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries—NP Bioinnovation A/S, Orocidin, and Bio-Convert—and its majority-owned subsidiary, NoviThera. All significant intercompany transactions have been eliminated in consolidation. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s Chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manages its business as a single operating segment. See Note 14 for more information. Translation Adjustment The reporting currency of the Company is U.S. Dollars. The accounts of the Company’s subsidiaries are maintained in Danish krone. In accordance with, Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Matters, all assets and liabilities are translated at the current exchange rate at respective balance sheets dates, stockholders’ equity transactions are translated at the historical rates and statement of operations accounts are translated at the average exchange rate for the period. The resulting translation adjustments are reported in other comprehensive income (loss) in accordance with ASC Topic 220, Reporting Comprehensive Income (“ASC 220”) in the condensed consolidated statements of operations and in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net loss and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income (loss) is inclusive of net loss and foreign currency translation adjustments. Research and Development Costs Research and development costs consists primarily of costs associated with Orocidin, Bio-Convert, and NoviThera’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Stock-based Compensation The Company accounts for stock-based compensation using the provisions of ASC Topic 718, Stock Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures as they occur. Compensation cost for service awards is recognized using the straight-line method over the vesting period. Compensation cost for performance awards is recognized when the vesting condition becomes probable of occurring. Stock-based compensation is included in officer compensation, general and administrative, research and development, and consulting expense in the condensed consolidated statements of operations and comprehensive loss. Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments. Distinguishing Liabilities from Equity The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in the FASB ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, and whether the warrants meet all of the requirements for equity classification under ASC Topic 815, including whether the warrants are indexed to the Company’s Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and on the date of issuance and for liability-classified awards, remeasured to fair value at each balance sheet date thereafter. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized in change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive income (loss). Net Loss per Share Net loss per share is computed pursuant to ASC Topic 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of Common Stock and potentially outstanding shares of Common Stock during the period. As of March 31, 2026, there were 1,000,000 potentially dilutive shares of Common Stock from <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuRycuQ35PIc" title="Dilutive shares">75,000 equity-classified warrants and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKqpn88G79ge" title="Dilutive shares">925,000 stock options. As of March 31, 2025, there were <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3r1Ubg7O2X" title="Dilutive shares">900,000 potentially dilutive shares of common stock from equity-classified warrants. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share. Business Combinations The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the condensed consolidated financial statements from the acquisition date. Purchase Accounting Measurement Period Adjustments From time to time, the Company makes acquisitions accounted for as business combinations under ASC 805. Certain asset and liability values are initially recorded as provisional and may be adjusted during the measurement period as new information becomes available. Finalized valuations result in retrospective adjustments to reflect facts and circumstances that existed at the acquisition date. During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration for Bio-Convert, inclusive of non-cash consideration paid by the Company and in-process research and development. The measurement period adjustment resulted in (i) a $26,475,819 increase in in-process research and development recorded and (ii) recognition of a $<span id="xdx_900_ecustom--DeferredTaxLiabilitiesInProcessResearchAndDevelopment_iI_c20250331__dei--LegalEntityAxis__custom--BioConvertMember_zpCUFpyK1N9l" title="Deferred tax liabilities, in-process research and development">5,868,647 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill. During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration, inclusive of non-cash consideration paid by the Company and the fair value of non-controlling interest, and in-process research and development. The measurement period adjustment resulted in (i) a $450,000 net increase in total consideration paid, (ii) a $15,457,444 increase in in-process research and development recorded, and (iii) recognition of a $3,449,767 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill. Goodwill The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company’s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of the Company’s reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, operating results, probability-adjusted cash flows, discount rates and other market participant assumptions. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. The Company assesses goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge during the years ended March 31, 2026 and 2025. Indefinite-lived Intangible Assets The Company accounts for its indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and Other (“ASC 350”). Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain in-process research and development (IPR&D) assets acquired via the Company’s business combinations with Orocidin and Bio-Convert detailed in Note 10, for impairment by comparing their fair values to their carrying values. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, probability-adjusted development and commercialization assumptions, discount rates and other market participant assumptions. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values. The Company did not record an impairment charge during the years ended March 31, 2026 and 2025. Revenue Recognition The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> The Company signed an agreement with Orocidin for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Orocidin became a subsidiary in the quarter ended June 30, 2024, <span id="xdx_900_eus-gaap--Revenues_do_c20240401__20240630__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember__srt--ConsolidatedEntitiesAxis__srt--SubsidiaryIssuerMember_zOF7a5FSKDcd" title="Revenue recognized">no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction. The Company signed an agreement with Bio-Convert for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Bio-Convert became a subsidiary in the quarter ended December 31, 2024, <span id="xdx_90A_eus-gaap--Revenues_do_c20241001__20241231__srt--ConsolidatedEntitiesAxis__srt--SubsidiaryIssuerMember__us-gaap--BusinessAcquisitionAxis__custom--BioConvertAPSMember_zzGKLZLxe55j" title="Revenue recognized">no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction. Non-controlling Interests In accordance with ASC Topic 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Following the acquisition of <span id="xdx_90D_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zD2VRpiXFKd3" title="Ownership percentage acquired">95% of Orocidin in May 2024, the Company determined that Orocidin was a VIE, and that the Company was the primary beneficiary. While the Company owned 95% of Orocidin’s equity interests, the remaining equity interests in Orocidin were owned by unrelated third parties, and the agreement with these third parties provided the Company with greater voting rights. Accordingly, the Company consolidated its interest in Orocidin under the VIE rules and reflected the third parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests were not redeemable by the equity holders and were presented as part of permanent equity. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage. In November 2024, the Company acquired the remaining <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20241112__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zV42DdnDLbze" title="Ownership percentage acquired">5% interest in Orocidin. As a result, Orocdin became a wholly owned subsidiary and was no longer considered a VIE. The noncontrolling interest in Orocidin was derecognized from the Company’s condensed consolidated financial statements at the time of the acquisition of the remaining <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20241112__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zddN1bUTOwcb" title="Ownership percentage acquired">5% interest. Following the creation of NoviThera in October 2025 and the issuance of equity in NoviThera to Alteral, the Company determined that NoviThera was a VIE, and that the Company was the primary beneficiary. While the Company owned 50.1% of NoviThera’s equity interests, the remaining equity interests in NoviThera are owned by a related party, and the agreement with the related party provided the Company with greater voting rights based on each party’s equity interest. Accordingly, the Company consolidated its interest in NoviThera under the VIE rules and reflected the related parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity. The consolidated balance sheet as of March 31, 2026 includes balances for NoviThera of $4,616 of cash,$5,707 for prepaid expenses and other current assets, $12,556 for other assets, and $91,422 accounts payable and accrued expenses. Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. Income Taxes The following table summarizes the deferred income tax activity for the year ended March 31, 2026: SCHEDULE OF DEFERRED INCOME TAX ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_dei--LegalEntityAxis_custom--OrocidinASMember_ztdVqxN5IRl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_dei--LegalEntityAxis_custom--BioConvertASMember_zI3EDSz3ukDd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zysLhlxMd6qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43E_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iS_zJ5ofgTCwfU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,449,767</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,868,647</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,318,414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_zKI9Ae3YkeG1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,776</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">510,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">735,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_435_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iE_zuIY0EI0HKXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,675,543</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,378,824</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,054,367</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Recently Adopted Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09, effective March 31, 2026, in these consolidated financial statements. ASU 2023-09 only impacted the disclosures and did not otherwise impact the consolidated financial statements. See Note 12, Income Taxes, for disclosures related to the adoption of ASU 2023-09. Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. This ASU was further clarified by ASU 2025-01, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which was issued in December 2024. The new standards require disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standards will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of these accounting standard updates on its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

Reverse Stock Split On November 8, 2024, the Company effectuated a 1-for-10 reverse stock split of its issued and outstanding Common Stock, rounding up to account for any fractional shares. The reverse stock split had no effect on the Company’s authorized shares of Common Stock or Preferred Stock and the par value of both remained unchanged at $0.001. All Common Stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these condensed consolidated financial statements and related disclosures.

1-for-10 reverse stock split

0.001

Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill, and the fair value of assets acquired and liabilities assumed in business combinations.

Concentration of Credit Risk The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. The Company also maintains cash in foreign bank accounts that are not federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in its accounts. The Company believes it is not exposed to any significant credit risk on cash.

Cash and Cash Equivalents Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of March 31, 2026 and March 31, 2025.

Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries—NP Bioinnovation A/S, Orocidin, and Bio-Convert—and its majority-owned subsidiary, NoviThera. All significant intercompany transactions have been eliminated in consolidation.

Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s Chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manages its business as a single operating segment. See Note 14 for more information.

Translation Adjustment The reporting currency of the Company is U.S. Dollars. The accounts of the Company’s subsidiaries are maintained in Danish krone. In accordance with, Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Matters, all assets and liabilities are translated at the current exchange rate at respective balance sheets dates, stockholders’ equity transactions are translated at the historical rates and statement of operations accounts are translated at the average exchange rate for the period. The resulting translation adjustments are reported in other comprehensive income (loss) in accordance with ASC Topic 220, Reporting Comprehensive Income (“ASC 220”) in the condensed consolidated statements of operations and in accumulated other comprehensive income (loss) as a component of stockholders’ equity.

Comprehensive Income (Loss) Comprehensive income (loss) is comprised of net loss and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income (loss) is inclusive of net loss and foreign currency translation adjustments.

Research and Development Costs Research and development costs consists primarily of costs associated with Orocidin, Bio-Convert, and NoviThera’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.

Stock-based Compensation The Company accounts for stock-based compensation using the provisions of ASC Topic 718, Stock Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures as they occur. Compensation cost for service awards is recognized using the straight-line method over the vesting period. Compensation cost for performance awards is recognized when the vesting condition becomes probable of occurring. Stock-based compensation is included in officer compensation, general and administrative, research and development, and consulting expense in the condensed consolidated statements of operations and comprehensive loss.

Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments.

Distinguishing Liabilities from Equity The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in the FASB ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, and whether the warrants meet all of the requirements for equity classification under ASC Topic 815, including whether the warrants are indexed to the Company’s Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and on the date of issuance and for liability-classified awards, remeasured to fair value at each balance sheet date thereafter. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized in change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive income (loss).

Net Loss per Share Net loss per share is computed pursuant to ASC Topic 260, Earnings Per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of Common Stock and potentially outstanding shares of Common Stock during the period. As of March 31, 2026, there were 1,000,000 potentially dilutive shares of Common Stock from <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuRycuQ35PIc" title="Dilutive shares">75,000 equity-classified warrants and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250401__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zKqpn88G79ge" title="Dilutive shares">925,000 stock options. As of March 31, 2025, there were <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3r1Ubg7O2X" title="Dilutive shares">900,000 potentially dilutive shares of common stock from equity-classified warrants. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

1000000

75000

925000

900000

Business Combinations The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in the condensed consolidated financial statements from the acquisition date.

Purchase Accounting Measurement Period Adjustments From time to time, the Company makes acquisitions accounted for as business combinations under ASC 805. Certain asset and liability values are initially recorded as provisional and may be adjusted during the measurement period as new information becomes available. Finalized valuations result in retrospective adjustments to reflect facts and circumstances that existed at the acquisition date. During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration for Bio-Convert, inclusive of non-cash consideration paid by the Company and in-process research and development. The measurement period adjustment resulted in (i) a $26,475,819 increase in in-process research and development recorded and (ii) recognition of a $<span id="xdx_900_ecustom--DeferredTaxLiabilitiesInProcessResearchAndDevelopment_iI_c20250331__dei--LegalEntityAxis__custom--BioConvertMember_zpCUFpyK1N9l" title="Deferred tax liabilities, in-process research and development">5,868,647 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill. During the year ended March 31, 2025, the Company completed its determination of the fair values of purchase consideration, inclusive of non-cash consideration paid by the Company and the fair value of non-controlling interest, and in-process research and development. The measurement period adjustment resulted in (i) a $450,000 net increase in total consideration paid, (ii) a $15,457,444 increase in in-process research and development recorded, and (iii) recognition of a $3,449,767 deferred tax liability associated with the in-process research and development asset. The net effect of such measurement period adjustments was recorded as an adjustment to goodwill. 26475819 5868647 450000 15457444 3449767

Goodwill The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company’s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of any of the Company’s reporting units is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of any of the reporting units is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, operating results, probability-adjusted cash flows, discount rates and other market participant assumptions. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded. The Company assesses goodwill for impairment on an annual basis as of March 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired. The Company did not record an impairment charge during the years ended March 31, 2026 and 2025.

Indefinite-lived Intangible Assets The Company accounts for its indefinite-lived intangible assets in accordance with ASC Topic 350, Intangibles - Goodwill and Other (“ASC 350”). Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain in-process research and development (IPR&D) assets acquired via the Company’s business combinations with Orocidin and Bio-Convert detailed in Note 10, for impairment by comparing their fair values to their carrying values. Fair value is estimated using an income approach based on discounted cash flow methodologies that incorporate significant assumptions including projected revenues, probability-adjusted development and commercialization assumptions, discount rates and other market participant assumptions. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values. The Company did not record an impairment charge during the years ended March 31, 2026 and 2025.

Revenue Recognition The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> The Company signed an agreement with Orocidin for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Orocidin became a subsidiary in the quarter ended June 30, 2024, <span id="xdx_900_eus-gaap--Revenues_do_c20240401__20240630__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember__srt--ConsolidatedEntitiesAxis__srt--SubsidiaryIssuerMember_zOF7a5FSKDcd" title="Revenue recognized">no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction. The Company signed an agreement with Bio-Convert for which it recognized $2,500 in revenue during the year ended March 31, 2025. Since Bio-Convert became a subsidiary in the quarter ended December 31, 2024, <span id="xdx_90A_eus-gaap--Revenues_do_c20241001__20241231__srt--ConsolidatedEntitiesAxis__srt--SubsidiaryIssuerMember__us-gaap--BusinessAcquisitionAxis__custom--BioConvertAPSMember_zzGKLZLxe55j" title="Revenue recognized">no more revenue is to be recognized under this agreement, but is eliminated as an intercompany transaction.

2500

Non-controlling Interests In accordance with ASC Topic 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Following the acquisition of <span id="xdx_90D_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zD2VRpiXFKd3" title="Ownership percentage acquired">95% of Orocidin in May 2024, the Company determined that Orocidin was a VIE, and that the Company was the primary beneficiary. While the Company owned 95% of Orocidin’s equity interests, the remaining equity interests in Orocidin were owned by unrelated third parties, and the agreement with these third parties provided the Company with greater voting rights. Accordingly, the Company consolidated its interest in Orocidin under the VIE rules and reflected the third parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests were not redeemable by the equity holders and were presented as part of permanent equity. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage. In November 2024, the Company acquired the remaining <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20241112__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zV42DdnDLbze" title="Ownership percentage acquired">5% interest in Orocidin. As a result, Orocdin became a wholly owned subsidiary and was no longer considered a VIE. The noncontrolling interest in Orocidin was derecognized from the Company’s condensed consolidated financial statements at the time of the acquisition of the remaining <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20241112__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zddN1bUTOwcb" title="Ownership percentage acquired">5% interest. Following the creation of NoviThera in October 2025 and the issuance of equity in NoviThera to Alteral, the Company determined that NoviThera was a VIE, and that the Company was the primary beneficiary. While the Company owned 50.1% of NoviThera’s equity interests, the remaining equity interests in NoviThera are owned by a related party, and the agreement with the related party provided the Company with greater voting rights based on each party’s equity interest. Accordingly, the Company consolidated its interest in NoviThera under the VIE rules and reflected the related parties’ interests in the condensed consolidated financial statements as a non-controlling interest. The Company recorded this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. Income and losses were allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity. The consolidated balance sheet as of March 31, 2026 includes balances for NoviThera of $4,616 of cash,$5,707 for prepaid expenses and other current assets, $12,556 for other assets, and $91,422 accounts payable and accrued expenses.

0.95

0.05

0.501

4616

5707

12556

91422

Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of research and development, clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.

Income Taxes The following table summarizes the deferred income tax activity for the year ended March 31, 2026: SCHEDULE OF DEFERRED INCOME TAX ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_dei--LegalEntityAxis_custom--OrocidinASMember_ztdVqxN5IRl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_dei--LegalEntityAxis_custom--BioConvertASMember_zI3EDSz3ukDd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zysLhlxMd6qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43E_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iS_zJ5ofgTCwfU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,449,767</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,868,647</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,318,414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_zKI9Ae3YkeG1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,776</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">510,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">735,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_435_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iE_zuIY0EI0HKXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,675,543</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,378,824</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,054,367</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table summarizes the deferred income tax activity for the year ended March 31, 2026: SCHEDULE OF DEFERRED INCOME TAX ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B4_dei--LegalEntityAxis_custom--OrocidinASMember_ztdVqxN5IRl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_dei--LegalEntityAxis_custom--BioConvertASMember_zI3EDSz3ukDd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_zysLhlxMd6qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43E_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iS_zJ5ofgTCwfU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,449,767</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,868,647</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,318,414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_zKI9Ae3YkeG1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,776</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">510,177</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">735,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_435_c20250401__20260331_eus-gaap--DeferredIncomeTaxLiabilitiesNet_iE_zuIY0EI0HKXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,675,543</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,378,824</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,054,367</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3449767

5868647

9318414

225776

510177

735953

3675543

6378824

10054367

Recently Adopted Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This Update enhances the transparency and usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. The guidance also eliminates certain existing requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The amendments in this Update are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09, effective March 31, 2026, in these consolidated financial statements. ASU 2023-09 only impacted the disclosures and did not otherwise impact the consolidated financial statements. See Note 12, Income Taxes, for disclosures related to the adoption of ASU 2023-09.

Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. This ASU was further clarified by ASU 2025-01, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which was issued in December 2024. The new standards require disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standards will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of these accounting standard updates on its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN The Company’s consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has recognized nominal revenue and has incurred losses since inception resulting in an accumulated deficit of $50,786,534 and held cash of $20,878 as of March 31, 2026. As a result, the Company’s current funds will not be sufficient to meet its needs for more than twelve months from the date of issuance of these condensed consolidated financial statements. Accordingly, there is substantial doubt about the ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company’s recent acquisitions, its generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock. In April 2026, the Company issued to a certain private investor for a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260401__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKNkF7RczRD9" title="Number of restricted shares issued">45,000 restricted shares of its common stock, par value $<span id="xdx_909_eus-gaap--CommonStockNoParValue_iI_c20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMSE15BmETZ" title="Common stock par value">0.001 per share. The price per share was $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvZUpJAC57Jc" title="Shares issued price per share">2.75 for gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromOtherEquity_pn5n6_c20260401__20260430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3vUV2WIiv56" title="Gross proceeds from issuance of restricted stock">0.1 million. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

-50786534

20878

45000

0.001

2.75

100000

NOTE 4 - INVESTMENTS On June 20, 2023, the Company and GK Partners ApS entered into a Stock Purchase and Sale Agreement, under which GK Partners ApS sold to the Company <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zV2yVZDngrr9" title="Number of shares issued">5,000,000 restricted shares of common stock of Mag Mile Capital. The shares were restricted in that they were subject to a registration statement being filed on Form S-1 by Mag Mile on September 6, 2023. The Form S-1 became effective on July 5, 2024, removing the restriction on the shares. In exchange, the Company issued <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUd9EqpEORf6" title="Number of shares issued">250,000 restricted shares of its Common Stock to GK Partners ApS. The shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0m1VxagVxag" title="Stock issued during period, value">1,750,000, at a price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z307OIcwwyBk" title="Common stock price per share">7.00 per share, the closing stock price for the Company’s Common stock on the last business day before the agreement. The Company accounts for its investment under the guidance of ASC Topic 321, Investments – Equity Securities, which provides guidance for equity interests that meet the definition of an equity security. Equity interests with readily determinable fair values are carried at fair value with changes in value recorded in earnings. Investments without readily determinable fair values are accounted for using the measurement alternative which is at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There is an active market for the shares of Mag Mile as of March 31, 2026. Therefore, the investment had an observable change in the value of Mag Mile’s shares that can be used to adjust the value of the Company’s investment in those shares. During the year ended March 31, 2026, the Company observed price changes to the trading price per share of Mag Mile’s common stock and recorded an increase of $325,000 in the Company’s investment. Prior to December 31, 2024, there was no active market for the shares of Mag Mile and the Company carried the investment at cost until such time that there was an indicator of impairment or an observable change in the value of Mag Mile’s shares that could be used to adjust the value of the Company’s investment in those shares. Prior to there being an active market for the shares of Mag Mile, no impairment of the carrying value of the investment was recorded.

5000000

250000

1750000

7.00

325000

NOTE 5 - RELATED PARTY TRANSACTIONS Mr. Tom Glasner Larsen is the spouse of Mrs. Glaesner, CEO of GK Partners, and was a member of our board of directors from February 23, 2023 until his voluntary retirement on June 9, 2023. He was a beneficial owner of a controlling interest in NP Bioinnovation A/S (formerly Managementselskabet af 12.08.2020 A/S) until its acquisition by the Company on February 23, 2023. He was also a beneficial owner of a controlling interest in Orocidin until its acquisition by the Company on May 13, 2024, and a beneficial owner of a controlling interest in Bio-Convert until its acquisition by the Company on November 11, 2024. Effective April 1, 2022, we issued to GK Partners, for financial services, a warrant (the “2022 GK Warrant”) to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_z4JNxCsxO8Qa" title="Warrant to purchase common stock">600,000 shares of our Common Stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zW7x6Q687Ejj" title="Exercise price of warrants">10.00 per share, and which had an expiration date of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zermOCxTiI5g" title="Warrant expiration date">December 31, 2023. The Company determined that the 2022 GK Warrant was not precluded from equity classification and was therefore recorded within additional paid-in capital on the Company’s consolidated balance sheets at its issuance date fair value. On December 22, 2023, the expiration date of the warrant, covering <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_z1Orh3zvhxq6" title="Number of unexercised warrant shares">570,500 remaining unexercised warrant shares, was extended to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zglcrNKF9Jne" title="Warrant expiration date">December 31, 2024. For the year ended March 31, 2025, GK Partners exercised a portion of its warrant for <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesExercisesOfWarrants_c20240401__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_z6iXcIvupMNc" title="Common stock issued on exercise of warrants">57,400 shares. The exercise price was $10.00 per share for total proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20240401__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zc4OlpUUZQ3a" title="Proceeds from warrant exercises">576,000. On <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zumlmcybZsHk" title="Warrant expiration date">December 31, 2024 the 2022 GK Warrant expired. Effective December 30, 2024, warrants were issued to GK Partners (the “2024 GK Warrant”) to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241230__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zqB7IeEKowg5" title="Warrant to purchase common stock">1,000,000 shares of the Company’s Common Stock at an exercise price equal to the greater of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241230__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zu828cIzyrr2" title="Exercise price of warrants">8.91 and the daily volume weighted average price of the Common Stock for the ten trading days immediately preceding the date of exercise. The 2024 GK Warrant was scheduled to expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241230__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zzoQgQ9Nmb2k" title="Warrant expiration date">December 31, 2025. The Company determined that the 2024 GK Warrant was precluded from being classified within equity and was liability classified under ASC Topic 815, Derivatives and Hedging. During the year ended March 31, 2025, GK Partners exercised a portion of its 2024 GK Warrant for a total of <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240401__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zJW7aIl6quU8" title="Common stock issued on exercise of warrants">35,176 shares. The exercise price ranged from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__srt--RangeAxis__srt--MinimumMember_zCN5132VdIaf" title="Warrant, exercise price">8.91 to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__srt--RangeAxis__srt--MaximumMember_zwm5n3paH8La" title="Warrant, exercise price">8.95 per share for total proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240401__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zPKRiru0S7bk" title="Proceeds from exercise of warrants">313,455. On March 31, 2025, the 2024 GK Warrant was terminated. Immediately prior to the termination, the fair value of the 2024 GK Warrant was $167,000, which was reclassified to additional paid in capital due to the related party relationship with GK Partners. As detailed in Note 4, on June 20, 2023, the Company and GK Partners entered into a Stock Purchase and Sale Agreement whereby the Company acquired equity interests in Mag Mile. During the year ended March 31, 2026, GK Partners purchased <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250401__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember_ziN2BdH6rJ1j" title="Number of shares purchased">49,000 shares of the Company’s common stock at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember_zvOd2NgxzmE5" title="Common stock price per share">5.00 per share for gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromOtherEquity_c20250401__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember_zE4ARnUwden" title="Gross proceeds">245,000. In July 2025, NP Bioinnovation A/S entered into a short-term lease agreement with GK Partners. NP Bioinnovation A/S incurred $<span id="xdx_90B_eus-gaap--OtherExpenses_c20250701__20250731__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersApsMember_zUYGmV5UCkYi" title="Incurred expenses">37,776 of expense related to the lease agreement. For the year ended March 31, 2026, GK Partners provided services to the Company’s subsidiaries totaling approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250401__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersApsMember_zWj5HEC7MPCc" title="Issued for services">126,658. Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $3,665 and $79,463 for the years ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and March 31, 2025, we had no outstanding payables due to the Affiliate for either period. Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to <span id="xdx_90C_ecustom--EmploymentAgreementExpirationDate_pid_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HenrikRoufMember_zJ3xhTGwRCK6" title="Employment agreement expiration date">April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Rouf’s annual salary to $360,000 and to extend the term to <span id="xdx_901_ecustom--EmploymentAgreementExpirationDate_pid_dd_c20250701__20250701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HenrikRoufMember_ztZhpanJfRxf" title="Employment agreement expiration date">July 1, 2026. Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and had a term of <span id="xdx_905_ecustom--EmploymentAgreementTerm_dc_c20230401__20230401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_z358kgDFiVf6" title="Employment agreement term">one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $60,000 and to extend the term to <span id="xdx_906_ecustom--EmploymentAgreementExpirationDate_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_zSdDNfdpZt54" title="Employment agreement expiration date">April 1, 2025. On July 1, 2025 the agreement was amended to increase Mr. Yankowitz’s annual salary to $120,000 and to extend the term to <span id="xdx_900_ecustom--EmploymentAgreementExpirationDate_dd_c20250701__20250701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_zmRKEiNUWMB" title="Employment agreement expiration date">July 1, 2026. During the year ended March 31, 2025, a related party forgave their payable of $13,886. The amount has been credited to additional paid in capital. Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of the Company, and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors. Mr. Hill-Madsen will continue as CEO of NP Bioinnovation A/S, of which the Company acquired 100% of the outstanding shares in exchange for shares of the Company on February 23, 2023. On June 3, 2024, the Company’s Board of Directors approved a compensation plan under which the Chairman of the Board of Directors will receive compensation of $20,000 per annum, and each other Director will receive compensation of $10,000 per annum, in consideration of their serving on the Corporation’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms. As of March 31, 2026, $15,000 is included in accounts payable and accrued expenses. On October 1, 2025, the Company entered into a consulting agreement with Darlington Group, LLC (“Darlington Group”), which is controlled by Andrew Ritter, a member of the Company’s board of directors. Darlington Group will provide consulting services concerning strategic guidance on U.S. capital markets and drug development; market access and network development; partnerships, industry intelligence and strategic planning; and operational support. The agreement is terminable by either party on 30 days’ advance notice. For these services, Darlington Group will be paid $10,000 in advance per quarter on each October 1, January 1, April 1 and July 1 during the term of the agreement, commencing October 1, 2025. In October 2025, the Company, through its subsidiary NoviThera, purchased intellectual property from Alteral in exchange for <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251031__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlteralTherapeuticsMember_z7QbuWGkPwDj" title="Equity method investment ownership percentage">49.9% equity stake in NoviThera, to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis. Mr. Allan Wehnert, who controls Alteral Therapeutics, was appointed CEO of NoviThera. As a result of the purchase, the Company retained a controlling 50.1% ownership interest in NoviThera. The Company expensed the acquired in-process research and development of $527,625 at the acquisition date because the assets had no alternative future use.

600000

10.00

2023-12-31

570500

2024-12-31

57400

10.00

576000

2024-12-31

1000000

8.91

2025-12-31

35176

8.91

8.95

313455

167000

49000

5.00

245000

37776

126658

3665

79463

72000

P1Y

120000

2025-04-01

360000

2026-07-01

36000

P1Y

60000

2025-04-01

120000

2026-07-01 13886

20000

10000

15000

10000

0.499

0.501

527625

NOTE 6 - FAIR VALUE MEASUREMENTS <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zNdJGtorQPw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and March 31, 2025: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zktKhZFu1ZTg" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsj9JqlzjwY3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3c1syieXxmc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z01qd7bD9LYg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InvestmentsFairValueDisclosure_iI_maAFVDz1bX_zDG1n3TKnJml" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Investment in Mag Mile Capital, Inc.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,250,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,250,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz1bX_zQ4PrOixHRW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztOzQJINDDRl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBczNqZePQ5e" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHELUJ8cgFmc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK1PNXIbxW2a" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InvestmentsFairValueDisclosure_iI_maAFVDz1bX_zNAWJFu8z2kc" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Investment in Mag Mile Capital, Inc.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">1,925,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">1,925,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz1bX_z9xoWWfE6M24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zNdJGtorQPw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and March 31, 2025: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zktKhZFu1ZTg" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsj9JqlzjwY3" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3c1syieXxmc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z01qd7bD9LYg" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InvestmentsFairValueDisclosure_iI_maAFVDz1bX_zDG1n3TKnJml" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Investment in Mag Mile Capital, Inc.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,250,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,250,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz1bX_zQ4PrOixHRW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztOzQJINDDRl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBczNqZePQ5e" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHELUJ8cgFmc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20250331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK1PNXIbxW2a" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InvestmentsFairValueDisclosure_iI_maAFVDz1bX_zNAWJFu8z2kc" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">Investment in Mag Mile Capital, Inc.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">1,925,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">1,925,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz1bX_z9xoWWfE6M24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2250000

1925000

NOTE 7 - PREFERRED STOCK Preferred Stock We have authorized 5,000,000 shares, $0.001 par value, preferred stock (the “Preferred Stock”) of which <span id="xdx_907_ecustom--PreferredStockIssuedAndRedeemedShares_pid_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEm9fAylZOc6" title="Preferred stock, shares issued and redeemed">500,000 shares have been issued and redeemed, and therefore are not considered outstanding. In addition, 500,000 shares of Preferred Stock have been designated as Series A Junior Participating Preferred Stock (the “Junior Preferred Stock”) with the designations and the powers, preferences, rights, qualifications, limitations and restrictions specified in the Certificate of Designation of the Junior Preferred Stock filed with the Delaware Department of State on January 28, 2008. Such number of shares may be increased or decreased by resolution of the Board of Directors, provided that no decrease shall reduce the number of shares of Junior Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Company that are convertible into Junior Preferred Stock. Each share of Junior Preferred Stock shall entitle the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. The holders of shares of Junior Preferred Stock, in preference to the holders of the Company’s Common Stock and of any other junior stock, shall be entitled to receive, when and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash. Upon the Company’s liquidation, dissolution or winding up, no distribution shall be made to the holders of shares of stock ranking junior to the Junior Preferred Stock unless, prior thereto, the holders of shares of Junior Preferred Stock shall have received $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pid_do_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorMember_zHD7DtKRFhEd" title="Preferred stock, liquidation value per share">100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon. The Junior Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of Preferred Stock. As of March 31, 2026 and March 31, 2025, there are <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20260331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockUndesignatedMember_zUgpuTSeWrVj" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20260331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockUndesignatedMember_zNdaX03KxWo5" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockUndesignatedMember_zDCv21Gz5NK6" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20250331__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockUndesignatedMember_zqBh2HwGXG02" title="Preferred stock, shares outstanding">no shares of Junior Preferred Stock or undesignated Preferred Stock issued and outstanding.

5000000

0.001

500000

Each share of Junior Preferred Stock shall entitle the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders.

100

NOTE 8 - COMMON STOCK TRANSACTIONS The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share (the “Common Stock”). Holders of the Company’s Common Stock are entitled to one vote for each share. During the year ended March 31, 2026, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250401__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateInvestorsMember_z9dk6yWmC6X1" title="Number of shares issued">1,850,036 shares of restricted Common Stock to private investors. The purchase price ranged from $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateInvestorsMember__srt--RangeAxis__srt--MinimumMember_zPbz1HjLAxY6" title="Share price">1.90-<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateInvestorsMember__srt--RangeAxis__srt--MaximumMember_zRbFUwu0LSOe" title="Share price">5.00 per share, resulting in total net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250401__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PrivateInvestorsMember_zbrNmHAlLPTj" title="Net proceeds">4.4 million. In August 2025, the Company’s Board of Directors authorized a share repurchase program which permits the Company to repurchase up to an aggregate of <span id="xdx_90C_esrt--StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_iI_c20250831__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zMiSW4Nu1jK9" title="Number of shares authorized, share repurchase program">200,000 shares of the Company’s Common Stock from existing shareholders only, solely in privately negotiated transactions, at a purchase price per share not greater than the then-current market price as determined based on the last reported sale price of the Company’s Common Stock on the Company’s principal trading market. The Company is not obligated to repurchase any shares and may suspend or terminate the program at any time. Repurchased shares may be held as treasury stock or retired, as determined by the Company. The repurchase program will remain in effect until the earliest of (i) the repurchase of 200,000 shares, (ii) 12 months from the date the program was authorized, or (iii) revocation by further Board action. On October 1, 2025, the Company repurchased 57,642 shares of Common Stock from an existing shareholder for $1.36 per share. The repurchase was made pursuant to the share repurchase program authorized by the Company’s Board of Directors. Following the transaction, <span id="xdx_900_esrt--StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_iI_c20251001__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znuEZOgHeF3l" title="Number of shares authorized to repurchased">142,358 shares remain authorized for repurchase.

50000000

0.001

1850036

1.90

5.00

4400000

200000 Repurchased shares may be held as treasury stock or retired, as determined by the Company. The repurchase program will remain in effect until the earliest of (i) the repurchase of 200,000 shares, (ii) 12 months from the date the program was authorized, or (iii) revocation by further Board action.

57642

1.36

142358

NOTE 9 - STOCK-BASED COMPENSATION In June 2024, the Company established the Nordicus Partners Corporation 2024 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key people with incentives to improve stockholder value and to contribute to the growth and financial success of the Company, and (ii) enabling the Company to attract, retain and reward the best-available persons. The Plan permits the granting of stock options (including incentive stock options qualifying under Code Section 422 and nonqualified stock options), stock appreciation rights (SARs), restricted or unrestricted stock awards, restricted stock units, performance awards, other stock-based awards, or any combination of the foregoing. Participation in the Plan shall be open to all employees, officers, directors, and consultants of the Company, or of any affiliate of the Company, as may be selected by the Company from time to time. However, only employees of the Company, and of any parent or subsidiary of the Company, shall be eligible for the grant of an incentive stock option. The grant of an award at any time to any person shall not entitle that person to a grant of an award at any future time. The shares of Common Stock that may be issued with respect to awards granted under the Plan shall not exceed an aggregate of 7,000,000 shares of Common Stock. The maximum number of shares of Common Stock under the Plan that may be issued as incentive stock options shall be <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionsMember_zTGb1WDmIKWe" title="Common stock authorized for issuance">7,000,000 shares. Regarding performance-based award limitations, the number of shares of Common Stock that may be granted in the form of options, SARs, restricted stock awards, restricted stock units, or performance award shares in a single fiscal year to a participant may not exceed <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zXPBCGdBxD8e" title="Common stock authorized for issuance">2,000,000 of each form. The following table summarizes the Company’s stock option activity under the Plan for the year ended March 31, 2026. Included in the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztuO9HTSmhh3" title="Share based compensation arrangements option grant fair value">925,000 outstanding options are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zlnOfHUIo8L6" title="Share based compensation arrangements option grant fair value">375,000 performance-based awards and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--ServiceSharesMember_zTOBCHALkEE" title="Number of stock options outstanding">550,000 service-based awards: SCHEDULE OF STOCK OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average Exercise Price per Option*</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250401__20260331_zSvAd2aXy7X" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning">825,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250401__20260331_fKg_____zNYUjLPbges1" style="width: 11%; text-align: right" title="Weighted average exercised price per options outstanding, beginning"> 3.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331_zPC9eOPq53Zc" title="Weighted average remaining contractual term">9.63</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250401__20260331_zza0gqt96Wi1" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding beginning">675,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250401__20260331_zipZ5lnytIO3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options, granted">100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250401__20260331_fKg_____zouarDysZskk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercised price per options , Granted">1.90</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250401__20260331_zlzB2NtMlPy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending">925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250401__20260331_fKg_____zqU4qLZ9LWs6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercised price per options outstanding, ending">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331_z3EH8GCq40f8" title="Weighted average remaining contractual term">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331_zG5aFsqqgrUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value outstanding ending">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable and vested as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250401__20260331_zgJjKQIKEE09" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock option outstanding, exercisable">550,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250401__20260331_fKg_____zi5RxBkRUpIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per option exercisable and vested">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331_zhawBJoIa0af" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual term exercisable and vested">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250401__20260331_zvchKCFs2vUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable and vested">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and expected to vest as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20260331_z8vdKh6SsCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock option outstanding, vested and expected">550,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260331_fKg_____zDzDlm6LxJn3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per option vested and expected">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331_zsYGGjZ1HXrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual term vested and expected">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20260331_zZ7ld7WDoQ77" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F0A_zGiIrCkH1cK" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">The weighted-average exercise price excludes the exercise price for the performance awards due to the variable nature of the exercise price. See below for more discussion of the performance awards.</td> </tr></table> The stock-based compensation expense related to option grants under the Plan was $137,544, for the year ended March 31, 2026 and was recognized within officer compensation on the Company’s consolidated statement of operations and comprehensive loss. All of the service based awards in the table above were fully vested at issuance and therefore all related compensation expense was recognized in the periods the awards were granted. There was <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20260331__us-gaap--AwardTypeAxis__custom--ServiceSharesMember_z7OACccKuEm" title="Unrecognized compensation cost">no unrecognized compensation cost related to the service based options as of March 31, 2026. The Performance Awards in the table above will fully vest when the vesting terms are met and expense will be recognized when the vesting event becomes probable. Therefore, no stock-based compensation expense was recorded for the Performance Awards for the year ended March 31, 2026. In November 2024, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20241130__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8HfU9wwvOFh" title="Number of awards issued">375,000 performance awards (the “Performance Awards”) were issued, whose vesting is dependent upon events related to future acquisitions that were not deemed probable of occurring at the time of grant through March 31, 2025. The exercise price of the Performance Awards will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date. Due to the variability in the exercise price of the Performance Awards, that is the exercise price will be equal to the closing price per share on the date preceding the vesting date, the Company concluded that the grant date was not established for accounting purposes. The fair value of the Performance Awards on the date of award was $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20241101__20241130__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zi4893T1Dfn4" title="Fair value of awards issued">671,250. As of March 31, 2026, the fair value of the Performance Awards was $<span id="xdx_90D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLYSr52VDBGg" title="Fair value of awards issued">924,000. The Company did not recognize compensation expense for such awards as the grant date has not been established nor is the achievement of the milestone considered probable. The Company will reassess the probability of achievement at each reporting date and will recognize compensation expense if and when the performance condition becomes probable of achievement. The weighted-average grant date fair value per share of options granted during the year ended March 31, 2026 was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250401__20260331_zDUvb3CTw4fl" title="Weighted-average grant date fair value of options granted">1.38. The Company uses the Black-Scholes option model to estimate the fair value of stock options. In applying the Black-Scholes option model, the Company used the following assumptions in the valuation of options granted in 2026: SCHEDULE OF FAIR VALUE STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250401__20260331_zXTtgCmiF8o7" style="width: 16%; text-align: right" title="Expected volatility">92</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250401__20260331_zRvG7liLg8g6" style="text-align: right" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331_zQbv2COK19K1" style="text-align: right" title="Exercise price">1.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20260331_zAED86bkfcAh" style="text-align: right" title="Stock price">1.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zn9MQ3uFt1I8" style="text-align: right" title="Expected term (years)">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250401__20260331_zSSEkFSMnTYh" style="text-align: right" title="Risk-free rate">3.80</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--MonteCarloMember_zDlnI60Bo4D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Due to the variability of the exercise price, which will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date, the Company uses a Monte Carlo simulation model to estimate the fair value of the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zSejtDj00aKc" title="Performance awards were vesting">375,000 Performance Awards where vesting was not probable as of March 31, 2026. In applying the Monte Carlo simulation model, the Company used the following assumptions in the valuation of the Performance Awards as of March 31, 2026: SCHEDULE OF FAIR VALUE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td> </td> <td colspan="2" id="xdx_982_ecustom--ShareBasedCompensationArrangementOfShareBasedPaymentAwardFairValueAssumptionsExercisePriceDescription_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_ztYPp6FtEB04" style="text-align: right" title="Exercise price">Variable</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Contractual term (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zug1vkLvRL64" style="width: 16%; text-align: right" title="Contractual term (years)">8.63</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zQllXvnc7CKl" style="text-align: right" title="Volatility (annual)">73</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zaSVz5uLQc58" style="text-align: right" title="Risk-free rate">4.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zoUFdbyMdif2" style="text-align: right" title="Dividend yield (per share)">0</td><td style="text-align: left">%</td></tr> </table> Equity issued for consulting services For the years ended March 31, 2026 and 2025, unrelated to the Plan, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250401__20260331__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zwvIkdWf7B32" title="Number of common stock issued for consulting services">84,000 and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20250331__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zyOsBWuqRPw6" title="Number of common stock issued for consulting services">30,000 shares of Common Stock to a third party for consulting services, respectively, which were valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250401__20260331__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_z4xEFHFdQ8Fe" title="Value of common stock issued for consulting services">304,000 and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240401__20250331__srt--TitleOfIndividualAxis__custom--ThirdPartyMember_zZ0d17nz8kd6" title="Value of common stock issued for consulting services">138,979, respectively, and recorded with general and administrative expense.

7000000

2000000

The following table summarizes the Company’s stock option activity under the Plan for the year ended March 31, 2026. Included in the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztuO9HTSmhh3" title="Share based compensation arrangements option grant fair value">925,000 outstanding options are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zlnOfHUIo8L6" title="Share based compensation arrangements option grant fair value">375,000 performance-based awards and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--ServiceSharesMember_zTOBCHALkEE" title="Number of stock options outstanding">550,000 service-based awards: SCHEDULE OF STOCK OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average Exercise Price per Option*</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250401__20260331_zSvAd2aXy7X" style="width: 11%; text-align: right" title="Number of stock options outstanding, beginning">825,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250401__20260331_fKg_____zNYUjLPbges1" style="width: 11%; text-align: right" title="Weighted average exercised price per options outstanding, beginning"> 3.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331_zPC9eOPq53Zc" title="Weighted average remaining contractual term">9.63</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250401__20260331_zza0gqt96Wi1" style="width: 11%; text-align: right" title="Aggregate intrinsic value outstanding beginning">675,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250401__20260331_zipZ5lnytIO3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of stock options, granted">100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250401__20260331_fKg_____zouarDysZskk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercised price per options , Granted">1.90</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250401__20260331_zlzB2NtMlPy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options outstanding, ending">925,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250401__20260331_fKg_____zqU4qLZ9LWs6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercised price per options outstanding, ending">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331_z3EH8GCq40f8" title="Weighted average remaining contractual term">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250401__20260331_zG5aFsqqgrUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value outstanding ending">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable and vested as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250401__20260331_zgJjKQIKEE09" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock option outstanding, exercisable">550,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250401__20260331_fKg_____zi5RxBkRUpIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per option exercisable and vested">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331_zhawBJoIa0af" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual term exercisable and vested">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250401__20260331_zvchKCFs2vUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value exercisable and vested">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Vested and expected to vest as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20260331_z8vdKh6SsCJ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock option outstanding, vested and expected">550,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20260331_fKg_____zDzDlm6LxJn3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per option vested and expected">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250401__20260331_zsYGGjZ1HXrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual term vested and expected">8.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20260331_zZ7ld7WDoQ77" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value vested and expected">135,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F0A_zGiIrCkH1cK" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">The weighted-average exercise price excludes the exercise price for the performance awards due to the variable nature of the exercise price. See below for more discussion of the performance awards.</td> </tr></table>

925000

375000

550000

825000

3.25

P9Y7M17D

675000

100000

1.90

925000

3.00

P8Y8M15D

135000

550000

3.00

P8Y8M15D

135000

550000

3.00

P8Y8M15D

135000

137544

375000

671250

924000

1.38

SCHEDULE OF FAIR VALUE STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250401__20260331_zXTtgCmiF8o7" style="width: 16%; text-align: right" title="Expected volatility">92</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250401__20260331_zRvG7liLg8g6" style="text-align: right" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331_zQbv2COK19K1" style="text-align: right" title="Exercise price">1.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20260331_zAED86bkfcAh" style="text-align: right" title="Stock price">1.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331_zn9MQ3uFt1I8" style="text-align: right" title="Expected term (years)">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250401__20260331_zSSEkFSMnTYh" style="text-align: right" title="Risk-free rate">3.80</td><td style="text-align: left">%</td></tr> </table>

0.92

1.90

P5Y

0.0380

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--MonteCarloMember_zDlnI60Bo4D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Due to the variability of the exercise price, which will be equal to the closing price per share of the Company’s common stock on the trading day preceding the vesting date, the Company uses a Monte Carlo simulation model to estimate the fair value of the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLLUJBU0VEIENPTVBFTlNBVElPTiAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zSejtDj00aKc" title="Performance awards were vesting">375,000 Performance Awards where vesting was not probable as of March 31, 2026. In applying the Monte Carlo simulation model, the Company used the following assumptions in the valuation of the Performance Awards as of March 31, 2026: SCHEDULE OF FAIR VALUE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise price</td><td> </td> <td colspan="2" id="xdx_982_ecustom--ShareBasedCompensationArrangementOfShareBasedPaymentAwardFairValueAssumptionsExercisePriceDescription_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_ztYPp6FtEB04" style="text-align: right" title="Exercise price">Variable</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Contractual term (years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zug1vkLvRL64" style="width: 16%; text-align: right" title="Contractual term (years)">8.63</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zQllXvnc7CKl" style="text-align: right" title="Volatility (annual)">73</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zaSVz5uLQc58" style="text-align: right" title="Risk-free rate">4.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividend yield (per share)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250401__20260331__us-gaap--AwardTypeAxis__custom--MonteCarloMember_zoUFdbyMdif2" style="text-align: right" title="Dividend yield (per share)">0</td><td style="text-align: left">%</td></tr> </table>

375000

Variable

P8Y7M17D

0.73

0.041

84000

30000

304000

138979

NOTE 10 - GOODWILL AND INTANGIBLE ASSETS Orocidin A/S On May 13, 2024, the Company and certain shareholders of Orocidin, a Danish stock corporation entered into a Stock Purchase and Sale Agreement (“Business Combination”), under which the Company issued 3,800,000 restricted shares of its Common Stock to the Sellers in exchange for <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_c20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zkLHZx6oqAo6" title="Voting interest percentage">95% of Orocidin’s outstanding shares of capital stock. The shares were valued at $5.00, the closing stock price of the Company on the date of acquisition. Orocidin is a preclinical-stage biotechnology company, and is developing a proprietary first-of-its-kind medical treatment for aggressive periodontitis. The Company accounted for the transaction as a business combination under ASC 805 and as a result, allocated the fair value of identifiable assets acquired and liabilities assumed as of the acquisition date. The excess of the purchase price over the estimated fair values of the underlying identifiable assets acquired, liabilities assumed was allocated to goodwill. The $<span id="xdx_90D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_c20240513__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_z8sgoaKoyCm1" title="Acquired intangible assets">15,680,760 of acquired intangible assets was assigned to IPR&D assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Orocidin’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Orocidin’s research and development activities related to its next generation of periodontitis therapies. On November 11, 2024, the Company acquired the remaining <span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20241111__20241111__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_z4n8lWcexYsj" title="Common shares acquired">29,663 outstanding common shares and voting interest, or <span id="xdx_90C_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_c20241111__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zHJPdCIcDiV5" title="Voting interest percentage">5.34%, of Orocidin. The acquisition-date fair value of the consideration transferred totaled $<span id="xdx_901_eus-gaap--BusinessCombinationConsiderationTransferred1_c20241111__20241111__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_z7008e19MFh6" title="Fair value of consideration transferred">650,000, which consisted of 200,000 shares of the Company’s Common Stock. The fair value of the 200,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25. Bio-Convert A/S On November 11, 2024 (the acquisition date), the Company acquired <span id="xdx_908_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_c20241111__us-gaap--BusinessAcquisitionAxis__custom--BioConvertASMember_zbUbTtvA1hO9" title="Voting interest percentage">100% of the outstanding common shares and voting interest of Bio-Convert. The Company accounted for the transaction as a business combination under ASC 805. Bio-Convert is a Denmark-based preclinical-stage biotechnology company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and when accompanied by dysplasia, it becomes a marker of disease progression and patients can potentially develop oral cancer. Bio-Convert is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation. This is achieved through a proprietary mucoadhesive oral topical formulation that delivers the drug without any systemic absorption. The aim of the treatment is therefore to eliminate the lesions or to reduce the malignant conversion rate of oral leukoplakia to oral cancer. The effect on oral cancer may improve the surgical removal procedure should this be needed for the oral cancer patients. Bio-Convert’s current plan is to conduct a pilot efficacy study in patients with oral leukoplakia. The acquisition-date fair value of the consideration transferred totaled $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_c20241111__20241111__us-gaap--BusinessAcquisitionAxis__custom--BioConvertASMember_z0rGg1O4cZu2" title="Fair value of consideration transferred">39,000,000, which consisted of 12,000,000 shares of the Company’s Common Stock. The fair value of the 12,000,000 common shares issued was determined based on the closing market price of the Company’s Common Stock on the acquisition date, $3.25. The $<span id="xdx_907_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_c20241111__us-gaap--BusinessAcquisitionAxis__custom--BioConvertASMember_zlbFm2MCYJCg" title="Acquired intangible assets">26,675,670 of acquired intangible assets was assigned to in-process research and development assets that was recognized at fair value on the acquisition date. To value the IPR&D, the Company utilized the Multi-Period Excess Earnings Method (“MPEEM”), under the Income Approach. The method considers the present value of excess earnings generated by Bio-Covert’s IPR&D after taking into account the cost to realize the revenue, charges for contributory assets and an appropriate discount rate to reflect the time value and risk associated with the invested capital. IPR&D acquired represents Bio-Convert’s research and development activities related to its new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation. The following table summarizes the goodwill activity for the year ended March 31, 2026: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--BusinessAcquisitionAxis_custom--OrocidinASMember_zMLEqijBTcea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--BusinessAcquisitionAxis_custom--BioConvertASMember_zGBQmZSvKEse" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_zU7xZoYuFLs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20250401__20260331_eus-gaap--Goodwill_iS_zefEwHTbrNtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,084,829</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,405,922</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">25,490,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_z25d2edEjgB2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">464,225</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,206,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,670,249</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20250401__20260331_eus-gaap--Goodwill_iE_zHMSuEZH0Bl4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,549,054</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,611,946</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,161,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the in-process research and development activity for the year ended March 31, 2026: SCHEDULE OF IN-PROCESS RESEARCH AND DEVELOPMENT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--BusinessAcquisitionAxis_custom--OrocidinASMember_zmBgwd46zcKi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_us-gaap--BusinessAcquisitionAxis_custom--BioConvertASMember_zQrQKs7LNfvk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_zgPWzyzT26rh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20250401__20260331_ecustom--InprocessResearchAndDevelopment_iS_zF0GNvS2MQFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">15,679,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">27,028,453</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">42,708,079</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--GainLossOnResearchAndDevelopmentForeignCurrencyTranslationAdjustment_zLRquDfh6mFk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,027,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,771,005</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,798,392</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43C_c20250401__20260331_ecustom--InprocessResearchAndDevelopment_iE_zpTbzDCGxjeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,707,013</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,799,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,506,471</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3800000

0.95

5.00

15680760

29663

0.0534

650000

200000

3.25

39000000

12000000

3.25

26675670

The following table summarizes the goodwill activity for the year ended March 31, 2026: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--BusinessAcquisitionAxis_custom--OrocidinASMember_zMLEqijBTcea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--BusinessAcquisitionAxis_custom--BioConvertASMember_zGBQmZSvKEse" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_zU7xZoYuFLs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20250401__20260331_eus-gaap--Goodwill_iS_zefEwHTbrNtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,084,829</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,405,922</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">25,490,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_z25d2edEjgB2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">464,225</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,206,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,670,249</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20250401__20260331_eus-gaap--Goodwill_iE_zHMSuEZH0Bl4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,549,054</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,611,946</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,161,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7084829

18405922

25490751

464225

1206024

1670249

7549054

19611946

27161000

The following table summarizes the in-process research and development activity for the year ended March 31, 2026: SCHEDULE OF IN-PROCESS RESEARCH AND DEVELOPMENT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--BusinessAcquisitionAxis_custom--OrocidinASMember_zmBgwd46zcKi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Orocidin</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_us-gaap--BusinessAcquisitionAxis_custom--BioConvertASMember_zQrQKs7LNfvk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bio-Convert</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_zgPWzyzT26rh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20250401__20260331_ecustom--InprocessResearchAndDevelopment_iS_zF0GNvS2MQFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">15,679,626</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">27,028,453</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">42,708,079</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--GainLossOnResearchAndDevelopmentForeignCurrencyTranslationAdjustment_zLRquDfh6mFk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,027,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,771,005</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,798,392</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43C_c20250401__20260331_ecustom--InprocessResearchAndDevelopment_iE_zpTbzDCGxjeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,707,013</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,799,458</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,506,471</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 15679626 27028453 42708079 1027387 1771005 2798392 16707013 28799458 45506471 NOTE 11 - WARRANTS A summary of the Company’s outstanding warrant activity for year ended March 31, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Contract</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 46%">Outstanding, March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze6Hk7hx7WP1" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding, Beginning balance">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNlRfAxrQjV2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">10.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzEsWAHuzAEl" title="Weighted Average Remaining Contractual term, Outstanding">2.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpujTCvi0jHi" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYRQSegymEg5" style="text-align: right" title="Weighted Average Exercise Price, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSzfvthhDOUd" style="text-align: right" title="Number of Warrants, Expired/cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zApE7cAb88Xg" style="text-align: right" title="Weighted Average Exercise Price, Expired/cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVSXwpuddL1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn39cnZ0pq54" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8NCpwfIopwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding, Ending balance">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmWYg68Xk1F4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">10.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIKlNLmd20x3" title="Weighted Average Remaining Contractual Term, Outstanding">1.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> All of the outstanding warrants are exercisable as of March 31, 2026 with an intrinsic value of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6x2GRc4Vosa" title="Warrants outstanding, intrinsic value">0.

A summary of the Company’s outstanding warrant activity for year ended March 31, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Contract</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 46%">Outstanding, March 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze6Hk7hx7WP1" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding, Beginning balance">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNlRfAxrQjV2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">10.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzEsWAHuzAEl" title="Weighted Average Remaining Contractual term, Outstanding">2.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpujTCvi0jHi" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYRQSegymEg5" style="text-align: right" title="Weighted Average Exercise Price, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSzfvthhDOUd" style="text-align: right" title="Number of Warrants, Expired/cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zApE7cAb88Xg" style="text-align: right" title="Weighted Average Exercise Price, Expired/cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVSXwpuddL1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn39cnZ0pq54" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8NCpwfIopwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding, Ending balance">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmWYg68Xk1F4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">10.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIKlNLmd20x3" title="Weighted Average Remaining Contractual Term, Outstanding">1.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

75000

10.00 P2Y9M

75000

10.00 P1Y9M

NOTE 12 - INCOME TAX Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated Staff Accounting Bulletin No. 118 regarding the impact of the decreased tax rates of the Tax Cuts & Jobs Act. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company and its subsidiaries file income tax returns in the U.S. and foreign jurisdictions. The U.S. federal and foreign jurisdiction income tax rates of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20250401__20260331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zjluLeOjmLX1" title="Foreign jurisdiction tax rate">21% and <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20250401__20260331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zC0pGEgYBJO7" title="Federal tax rate">22%, respectively, are being used. For financial reporting purposes, loss before provision for income taxes, includes the following components: SCHEDULE OF LOSS BEFORE PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20250401__20260331_zSOVvLA5tcQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20240401__20250331_zcrY73UguVt9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz3zG_zJuVmprcmON5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,279,724</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,378,769</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz3zG_zDf9h5TvoMhg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,767,080</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,538,511</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz3zG_zcj0fhvIZo4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,046,804</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,917,280</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The table below provides the updated requirements of ASU 2023-09 for 2025. See Notes to Consolidated Financial Statements - Income Taxes for additional details on the adoption of ASU 2023-09. The effective tax rate differs from the federal statutory income tax rate applied to the loss before provision for income taxes and tax due to the following: SCHEDULE OF RECONCILIATION OF TAXES ON INCOME <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span id="xdx_907_eus-gaap--TaxJurisdictionOfDomicileExtensibleEnumeration_dxL_c20250401__20260331_zqZRl4RDSAEd" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">Federal tax benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_mawalter_c20250401__20260331_zG5rjoZs12il" style="width: 16%; text-align: right" title="Federal tax benefit">(188,090</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maZos_c20250401__20260331_zLUJpSbIWzKg" style="width: 16%; text-align: right" title="Federal statutory tax rate">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign expense (benefit)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_mawalter_c20250401__20260331_zB0PD5VVsVWg" style="text-align: right" title="Foreign tax diffrential">3,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maZos_c20250401__20260331_zherhx9yApS2" style="text-align: right" title="Foreign tax diffrential">0.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Temporary differences</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationTemporaryDiffrences_mawalter_c20250401__20260331_zU24NHHMVOjc" style="text-align: right" title="Temporary differences">(39,366</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_maZos_c20250401__20260331_zDjUhbrxGMs" style="text-align: right" title="Temporary differences">(4.4</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance change</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_mawalter_c20250401__20260331_zSBywUmCXZv5" style="border-bottom: Black 1pt solid; text-align: right" title="Temporary differences">223,626</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maZos_c20250401__20260331_z5f9twM4Uoee" style="border-bottom: Black 1pt solid; text-align: right" title="Increase in valuation allowance">25.0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total income tax expense</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtwalter_c20250401__20260331_zrR2sOP07eZ7" style="text-align: right" title="Total Income tax expense">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtZos_c20250401__20260331_zmLlekpzh7jk" style="text-align: right" title="Effective tax rate">—</td><td style="text-align: left">%</td></tr> </table> As previously disclosed for the year ended March 31, 2025, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows: SCHEDULE OF RECONCILIATION ON EFFECTIVE TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240401__20250331_zSLcgOOKEVb8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maEitrco_zQC4jweSyEU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maEitrco_zA2xBiY1vOA2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_maEitrco_z2YTMFqkppaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maEitrco_zrIfgKNMOv62" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Increase in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16.8</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_mtEitrco_zMh8fBv5HEyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_897_ecustom--ScheduleOfDeferredTaxAssetsAndLiabilitiesDueToTemporaryDifferencesTableTextBlock_z6yZ7nKuODf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and deferred tax liabilities consist of the following: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_z2QUlnplmKW8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250331_zWOYkM8ChjDk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zY3TAWhWXn38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsStockBasedCompensation_i01I_maDTAGz7gO_zoswA3nLMQE7" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Stock-based compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,884</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz7gO_zJhcJZFOtOQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net operating loss carryforwards</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,302,399</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,253,078</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz7gO_maDTALNzpOd_zl8Ixy5GurA9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,331,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,253,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzpOd_zDGq4HFGcnI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,331,283</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,253,078</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzpOd_zq2lKA5vDa33" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ComponentsOfDeferredTaxLiabilitiesAbstract_iB_zUj9Azs0275k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iNI_di_maDITLzlVl_zsItwT51ZIel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">In-process research and development intangible assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzlVl_maDTLzmHk_zsHJVDIsqLi9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzmHk_zS5FKIcXqaAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,318,414</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,318,414</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> At March 31, 2026 and 2025, the Company had net operating loss carry forwards of approximately $25,190,000 and $24,941,000, respectively, that may be offset against future taxable income. During the years ended March 31, 2026 and 2025, the total change in the valuation allowance was $223,626 and $490,656, respectively. Net operating loss carryforwards of approximately $20,762,400 can be carried forward for 20 years and begin to expire in 2024. Net operating loss carryforward amounts of $10,732,500 can be carried forward indefinitely, but are limited to 80% of taxable income in any one year. The Company has net operating loss carryforwards that have resulted in deferred tax assets of approximately $5,302,399, of which $930,000 have no expiration date. The Company maintains certain earnings as indefinitely reinvested in operations outside of the United States, for which no deferred income taxes have been provided. Determination of the amount of unrecognized deferred tax liability, if any, associated with such earnings is not practicable. No tax benefit has been reported in the March 31, 2026, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. A portion of the Company’s deferred tax liability, totaling $735,953, relates to the income tax effect of foreign currency translation adjustments on its foreign subsidiaries, which was recorded through other comprehensive income The Company’s ability to use its net operating loss carryforwards may be substantially limited due to ownership change limitations that may occur as required by Section 382 of the Internal Revenue Code of 1986 as amended. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since incurring losses. If the Company has completed an ownership change, utilization of the net operating loss carryforwards would be subject to annual limitations under Section 382. Any limitation could result in expiration of a portion of the net operating loss carryforwards before utilization. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2016.

0.21

0.22

For financial reporting purposes, loss before provision for income taxes, includes the following components: SCHEDULE OF LOSS BEFORE PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20250401__20260331_zSOVvLA5tcQg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20240401__20250331_zcrY73UguVt9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz3zG_zJuVmprcmON5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,279,724</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,378,769</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOz3zG_zDf9h5TvoMhg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,767,080</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,538,511</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz3zG_zcj0fhvIZo4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,046,804</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,917,280</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-1279724

-1378769

-2767080

-1538511

-4046804

-2917280

The table below provides the updated requirements of ASU 2023-09 for 2025. See Notes to Consolidated Financial Statements - Income Taxes for additional details on the adoption of ASU 2023-09. The effective tax rate differs from the federal statutory income tax rate applied to the loss before provision for income taxes and tax due to the following: SCHEDULE OF RECONCILIATION OF TAXES ON INCOME <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span id="xdx_907_eus-gaap--TaxJurisdictionOfDomicileExtensibleEnumeration_dxL_c20250401__20260331_zqZRl4RDSAEd" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2026%23IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">Federal tax benefit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_mawalter_c20250401__20260331_zG5rjoZs12il" style="width: 16%; text-align: right" title="Federal tax benefit">(188,090</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_maZos_c20250401__20260331_zLUJpSbIWzKg" style="width: 16%; text-align: right" title="Federal statutory tax rate">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign expense (benefit)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_mawalter_c20250401__20260331_zB0PD5VVsVWg" style="text-align: right" title="Foreign tax diffrential">3,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maZos_c20250401__20260331_zherhx9yApS2" style="text-align: right" title="Foreign tax diffrential">0.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Temporary differences</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationTemporaryDiffrences_mawalter_c20250401__20260331_zU24NHHMVOjc" style="text-align: right" title="Temporary differences">(39,366</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_maZos_c20250401__20260331_zDjUhbrxGMs" style="text-align: right" title="Temporary differences">(4.4</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance change</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_mawalter_c20250401__20260331_zSBywUmCXZv5" style="border-bottom: Black 1pt solid; text-align: right" title="Temporary differences">223,626</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maZos_c20250401__20260331_z5f9twM4Uoee" style="border-bottom: Black 1pt solid; text-align: right" title="Increase in valuation allowance">25.0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total income tax expense</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtwalter_c20250401__20260331_zrR2sOP07eZ7" style="text-align: right" title="Total Income tax expense">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtZos_c20250401__20260331_zmLlekpzh7jk" style="text-align: right" title="Effective tax rate">—</td><td style="text-align: left">%</td></tr> </table>

-188090

0.210

3830

0.004

-39366 -0.044

223626

0.250

As previously disclosed for the year ended March 31, 2025, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows: SCHEDULE OF RECONCILIATION ON EFFECTIVE TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240401__20250331_zSLcgOOKEVb8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maEitrco_zQC4jweSyEU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maEitrco_zA2xBiY1vOA2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_maEitrco_z2YTMFqkppaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maEitrco_zrIfgKNMOv62" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Increase in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16.8</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_mtEitrco_zMh8fBv5HEyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

0.210

0.005

-0.047

-0.168

<p id="xdx_897_ecustom--ScheduleOfDeferredTaxAssetsAndLiabilitiesDueToTemporaryDifferencesTableTextBlock_z6yZ7nKuODf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and deferred tax liabilities consist of the following: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_z2QUlnplmKW8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250331_zWOYkM8ChjDk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zY3TAWhWXn38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsStockBasedCompensation_i01I_maDTAGz7gO_zoswA3nLMQE7" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Stock-based compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">28,884</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz7gO_zJhcJZFOtOQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net operating loss carryforwards</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,302,399</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,253,078</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz7gO_maDTALNzpOd_zl8Ixy5GurA9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,331,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,253,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzpOd_zDGq4HFGcnI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,331,283</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,253,078</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzpOd_zq2lKA5vDa33" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ComponentsOfDeferredTaxLiabilitiesAbstract_iB_zUj9Azs0275k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred Tax Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iNI_di_maDITLzlVl_zsItwT51ZIel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">In-process research and development intangible assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzlVl_maDTLzmHk_zsHJVDIsqLi9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,318,414</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzmHk_zS5FKIcXqaAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,318,414</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,318,414</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 28884

5302399

5253078

5331283

5253078

5331283

5253078

9318414

25190000

24941000

223626

490656

Net operating loss carryforwards of approximately $20,762,400 can be carried forward for 20 years and begin to expire in 2024. Net operating loss carryforward amounts of $10,732,500 can be carried forward indefinitely, but are limited to 80% of taxable income in any one year. The Company has net operating loss carryforwards that have resulted in deferred tax assets of approximately $5,302,399, of which $930,000 have no expiration date.

5302399

735953

NOTE 13 - NOTE PAYABLE On February 18, 2026, Nordicus Partners Corporation entered into a demand promissory note (the “Note”) with Reddington, in the aggregate amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20260218__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_z4QZyQCnOIn9" title="Promissory notes face value">40,000. The Note bears interest at a rate equal to the lesser of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260218__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_zXNdWAd1hpfb" title="Interest rate percent">6.0% per annum and the maximum rate permitted by applicable law. Interest is calculated on the basis of a 365-day year and actual days elapsed. The outstanding principal balance, together with all accrued and unpaid interest, is due and payable on demand by the Lender and, accordingly, is classified as a current liability on the balance sheet. In the event of default, including nonpayment or certain insolvency events, the Payee may declare all amounts immediately due and payable and may pursue customary remedies, including collection costs and attorneys’ fees. The Company may prepay the Note, in whole or in part, at any time without premium or penalty. Payments made under the Note are applied first to accrued interest and then to principal. On March 6, 2026, the Company entered into an additional demand promissory note with the same lender under substantially identical terms, pursuant to which the Company borrowed an additional $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20260306__us-gaap--DebtInstrumentAxis__custom--AdditionalDemandPromissoryNoteMember__dei--LegalEntityAxis__custom--ReddingtonMember_zEi0UsOqhhj7" title="Promissory notes face value">20,000. As of March 31, 2026 and 2025, the principal balance due was $<span id="xdx_901_eus-gaap--DebtInstrumentRepaidPrincipal_c20250401__20260331__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_zbq5RPPuI9dg" title="Principal amount due">60,000 and $<span id="xdx_90D_eus-gaap--DebtInstrumentRepaidPrincipal_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_zrzODEh40wz2" title="Principal amount due">0, respectively. The Company recorded accrued interest expense of $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20250401__20260331__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_zlStJv6oVg7f" title="Interest expenses">345 and $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--TwoDemandPromissoryNotesMember__dei--LegalEntityAxis__custom--ReddingtonMember_zoFdW3Gnxnb8" title="Interest expenses">0 for the years ended March 31, 2026 and 2025, respectively, which is included in accounts payable and accrued expenses on the consolidated balance sheets.

40000

0.060

20000

60000

345

NOTE 14 - SEGMENT REPORTING The Company operates as a single operating segment, which consists of the Company’s wholly-owned subsidiaries, Orocidin and Bio-Convert, and its majority-owned subsidiary, NoviThera. All subsidiaries are focused on developing medicines supporting oral health. The Company has one reportable segment, which consists of its single operating segment. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). When evaluating the Company’s financial performance and deciding how to allocate resources, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company-wide basis. The Company’s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results. The Company did not generate any revenue during the year ended March 31, 2026. The Company has no material intra-entity revenues or expenses. As the Company is currently in the pre-revenue phase, the aforementioned operating expenses are the primary drivers that guide decisions of future spending and to monitor performance. The measure of segment assets is reported on the balance sheet as total assets. The CODM does not separately evaluate performance by geographic region or product line, as the Company has not yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company’s operations are conducted within the United States of America and Denmark.

NOTE 15 - SUBSEQUENT EVENTS Management has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following: In March and April 2026, the Company issued to five private investors for a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260301__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zs6177PDi9Ah" title="Restricted shares"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zoDZJBf29rg2" title="Restricted shares">201,500 restricted shares of its common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockNoParValue_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zj0R4fM5FKY3" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockNoParValue_iI_c20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zC0VSLki6Hwb" title="Common stock, par value">0.001 per share. The price per share was $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zshKwvhOoYih" title="Price per share"><span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zWeHcpxJvsk7" title="Price per share">2.75 for gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260301__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_z9zGPqA7Snv7" title="Gross proceeds"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FivePrivateInvestorsMember_zuJLzNkxlUJe" title="Gross proceeds">0.6 million. In March through June 2026 an affiliate of our chief executive officer, Henrik Rouf, loaned to the company $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20260630__srt--TitleOfIndividualAxis__custom--HenrikRoufMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlz14hWVW76i" title="Promissory notes">22,000 pursuant to demand promissory notes bearing interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260301__20260630__srt--TitleOfIndividualAxis__custom--HenrikRoufMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzyy9LHowVD9" title="Promissory notes">6% per annum. On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors of the Company, effective immediately. He also resigned from the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board.

201500

0.001

2.75

600000

22000

0.06

true The weighted-average exercise price excludes the exercise price for the performance awards due to the variable nature of the exercise price. See below for more discussion of the performance awards.